The COMPASSION-15 phase III trial recently evaluated the efficacy and safety of cadonilimab plus chemotherapy (CAD-CHM) as a first-line treatment for HER2-negative advanced G/GEJ adenocarcinoma (21). Here, ERBB2 is linked to gastroesophageal junction adenocarcinoma.